Several analysts have recently updated their ratings and price targets for Revance Therapeutics (NASDAQ: RVNC):

  • 9/17/2018 – Revance Therapeutics was downgraded by analysts at JMP Securities from an “outperform” rating to a “market perform” rating.
  • 9/17/2018 – Revance Therapeutics had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies.
  • 9/15/2018 – Revance Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 9/14/2018 – Revance Therapeutics had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock. They wrote, “We expect upward earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. These could come from positive news flow for Revance’s key programs in development. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $50 and Overweight rating.””
  • 8/9/2018 – Revance Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance’s initial focus is on developing daxibotulinumtoxinA, the company’s highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. “
  • 8/2/2018 – Revance Therapeutics was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 8/2/2018 – Revance Therapeutics was given a new $50.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 7/25/2018 – Revance Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance’s initial focus is on developing daxibotulinumtoxinA, the company’s highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. “

RVNC traded down $0.08 during trading on Wednesday, hitting $24.05. The company’s stock had a trading volume of 8,946 shares, compared to its average volume of 308,614. The company has a market capitalization of $948.38 million, a PE ratio of -6.00 and a beta of 1.29. Revance Therapeutics Inc has a twelve month low of $22.25 and a twelve month high of $37.45.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.92) by ($0.02). The business had revenue of $0.69 million during the quarter, compared to analyst estimates of $0.93 million. Revance Therapeutics had a negative net margin of 13,690.62% and a negative return on equity of 63.30%. research analysts anticipate that Revance Therapeutics Inc will post -3.9 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of RVNC. Allianz Asset Management GmbH grew its stake in shares of Revance Therapeutics by 16.5% during the 1st quarter. Allianz Asset Management GmbH now owns 79,437 shares of the biopharmaceutical company’s stock valued at $2,447,000 after buying an additional 11,271 shares during the period. Sio Capital Management LLC purchased a new stake in shares of Revance Therapeutics during the 2nd quarter valued at $2,780,000. American International Group Inc. grew its stake in shares of Revance Therapeutics by 11.4% during the 1st quarter. American International Group Inc. now owns 17,205 shares of the biopharmaceutical company’s stock valued at $530,000 after buying an additional 1,765 shares during the period. Federated Investors Inc. PA grew its stake in shares of Revance Therapeutics by 52.9% during the 1st quarter. Federated Investors Inc. PA now owns 58,530 shares of the biopharmaceutical company’s stock valued at $1,802,000 after buying an additional 20,245 shares during the period. Finally, Wells Fargo & Company MN grew its stake in shares of Revance Therapeutics by 83.9% during the 1st quarter. Wells Fargo & Company MN now owns 25,635 shares of the biopharmaceutical company’s stock valued at $789,000 after buying an additional 11,695 shares during the period. Institutional investors own 94.35% of the company’s stock.

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.

Further Reading: Should You Consider an Index Fund?

Receive News & Ratings for Revance Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.